Given the complexity and rapid evolution of cancer treatments, especially in the realm of targeted therapies and precision medicine, there may be new developments and clinical trials focusing on the OCT4/VCC-1 axis in lung cancer. This evidence concerns the gene POU5F1 and lung carcinoma.